Clinical Trial Update: 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder [Phase 3]

View source ↗

Summary

A Phase 3, 24-week, placebo-controlled trial of flibanserin in premenopausal women with hypoactive sexual desire disorder has completed and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• ADDYI (flibanserin)

Snippet

Sponsor: Sprout Pharmaceuticals, Inc | Conditions: Sexual Dysfunctions, Psychological | Phase 3 | Status: COMPLETED | Results posted: 2016-06-27